<p>药明康德（NASDAQ:BMRN - 获取免费报告）在周一发布的研究报告中，华尔街的分析师将其目标价格从 124.00 美元下调至 104.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。摩根大通的价格目标显示出该公司股价从之前的收盘价有 66.81% 的潜在上涨空间。</p>
<ul>
<li>药明康德的股票能否满足华尔街的高期望？</li>
</ul>
<p>其他几位研究分析师最近也对该公司发表了看法。StockNews.com 在 4 月 25 日的研究报告中将药明康德的评级从 “买入” 上调至 “强力买入”。加拿大丰业银行在 2 月 20 日的研究报告中将药明康德的目标价格从 78.00 美元上调至 80.00 美元，并给予该公司 “行业表现” 评级。美国银行在 2 月 20 日的研究报告中将药明康德的目标价格从 99.00 美元上调至 103.00 美元，并给予该股票 “买入” 评级。加拿大皇家银行在 2 月 20 日的研究报告中重申了 “行业表现” 评级，并将药明康德的目标价格设定为 70.00 美元。最后，Wedbush 在 2 月 20 日的研究报告中重新发布了 “跑赢大盘” 评级，并将药明康德的目标价格设定为 94.00 美元。七位分析师对该股票给予持有评级，十七位分析师给予买入评级，一位分析师给予强力买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 93.45 美元。</p>
<p><strong>查看我们对药明康德的最新分析</strong></p>
<h2>药明康德的价格表现</h2>
<ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
<p>NASDAQ:BMRN 在周一的交易中上涨 0.32 美元，达到 62.35 美元。该股票交易了 214,200 股，较其平均交易量 1,857,035 股有所减少。该公司的市值为 119 亿美元，市盈率为 28.39，市盈增长比率为 0.61，贝塔值为 0.27。药明康德的 1 年最低价为 52.93 美元，1 年最高价为 94.85 美元。该股票的 50 日移动平均价格为 65.84 美元，200 日移动平均价格为 65.71 美元。该公司的速动比率为 2.62，流动比率为 5.33，债务股本比率为 0.11。</p>
<p>药明康德（NASDAQ:BMRN - 获取免费报告）最近在 2 月 19 日发布了其财报。这家生物技术公司报告本季度每股收益为 0.72 美元，超出市场共识预期的 0.54 美元，超出幅度为 0.18 美元。药明康德的净利润率为 14.96%，股本回报率为 9.91%。该公司本季度的收入为 7.4731 亿美元，超过市场共识预期的 7.1105 亿美元。卖方分析师预测药明康德在当前财政年度将发布 3.15 美元的每股收益。</p>
<h2>药明康德的内部买卖情况</h2>
<ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
<p>在其他新闻中，首席会计官 Erin Burkhart 在 3 月 19 日的交易中出售了 1,295 股该公司的股票。这些股票的平均售价为 71.52 美元，总价值为 92,618.40 美元。交易后，首席会计官现在直接持有该公司 16,955 股股票，价值约为 1,212,621.60 美元。这代表着他们持有的股票减少了 7.10%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。目前，企业内部人士持有该股票的 0.85%。</p>
<h2>对药明康德的对冲基金看法</h2>
<p>对冲基金最近增加或减少了对该股票的持仓。挪威银行在第四季度购买了药明康德的新头寸，价值 234,645,000 美元。资本研究全球投资者在第四季度将其在药明康德的持股增加了 23.8%。资本研究全球投资者目前持有药明康德的 12,991,772 股股票，价值 853,944,000 美元，在此期间又购买了 2,496,817 股。Soleus Capital Management L.P.在第四季度购买了药明康德的新股份，价值约为 65,822,000 美元。Dodge &amp; Cox 在第四季度将其在药明康德的持股增加了 6.1%。Dodge &amp; Cox 目前持有药明康德的 14,746,235 股股票，价值 969,270,000 美元，在此期间又收购了 847,917 股。最后，AQR 资本管理公司在第四季度将其在药明康德的持股增加了 114.5%。AQR 资本管理公司目前持有药明康德的 1,283,599 股股票，价值 84,371,000 美元，在上个季度又收购了 685,099 股。目前，98.71% 的股票由机构投资者持有。</p>
<h2>药明康德公司简介</h2>
<p>（获取免费报告）</p>
<p>药明康德公司开发和商业化针对严重和危及生命的罕见疾病及医疗状况的治疗方案。其商业产品包括 Vimizim，一种用于治疗粘多糖贮积症（MPS）IV 型 A 的酶替代疗法；Naglazyme，一种用于 MPS VI 患者的重组 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的专有合成口服 6R-BH4。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过药明康德</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>比特币再次接近 10 万美元时的 3 只关注股票</li>
<li>万亿美元市值的意义超越数字</li>
<li>亚马逊：伟大反弹的原因可能即将开始</li>
<li>3 只小盘股具有大幅回报潜力</li>
<li>3 个理由说明特斯拉应该在 6 月成为 300 美元的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在拜玛林制药吗？</h2>
<p>在考虑拜玛林制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而拜玛林制药并不在名单上。</p>
<p>虽然拜玛林制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

拜玛林制药

<p>高盛集团已将拜玛林制药（NASDAQ:BMRN）的目标股价从 124.00 美元下调至 104.00 美元，同时维持 “买入” 评级。这一调整暗示相较于前一交易日收盘价有 66.81% 的潜在上涨空间。其他分析师也给出了混合的评级和目标价格，普遍评级为 “适度买入”，平均目标价格为 93.45 美元。拜玛林的股票交易价格为 62.35 美元，市值为 119 亿美元，最近的财报显示出积极的结果</p>

<p>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) had its target price lowered by stock analysts at The Goldman Sachs Group from $124.00 to $104.00 in a research report issued on Monday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the biotechnology company's stock. The Goldman Sachs Group's price objective points to a potential upside of 66.81% from the company's previous close.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:BMRN - 获取免费报告）在周一发布的研究报告中，华尔街的分析师将其目标价格从 124.00 美元下调至 104.00 美元，Benzinga 报道。该公司目前对这家生物技术公司的股票给予 “买入” 评级。摩根大通的价格目标显示出该公司股价从之前的收盘价有 66.81% 的潜在上涨空间。</p>
</div><ul>
<li>Can BioMarin Stock Live Up to Wall Street’s High Expectations?</li>
</ul>
<div class="lb-trans"><ul>
<li>药明康德的股票能否满足华尔街的高期望？</li>
</ul>
</div><p>Several other research analysts also recently weighed in on the company. StockNews.com upgraded BioMarin Pharmaceutical from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research note on Friday, April 25th. Scotiabank raised their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a &#34;sector perform&#34; rating in a research note on Thursday, February 20th. Bank of America boosted their price target on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, February 20th. Royal Bank of Canada restated a &#34;sector perform&#34; rating and set a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Finally, Wedbush reissued an &#34;outperform&#34; rating and set a $94.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Seven analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $93.45.</p>
<div class="lb-trans"><p>其他几位研究分析师最近也对该公司发表了看法。StockNews.com 在 4 月 25 日的研究报告中将药明康德的评级从 “买入” 上调至 “强力买入”。加拿大丰业银行在 2 月 20 日的研究报告中将药明康德的目标价格从 78.00 美元上调至 80.00 美元，并给予该公司 “行业表现” 评级。美国银行在 2 月 20 日的研究报告中将药明康德的目标价格从 99.00 美元上调至 103.00 美元，并给予该股票 “买入” 评级。加拿大皇家银行在 2 月 20 日的研究报告中重申了 “行业表现” 评级，并将药明康德的目标价格设定为 70.00 美元。最后，Wedbush 在 2 月 20 日的研究报告中重新发布了 “跑赢大盘” 评级，并将药明康德的目标价格设定为 94.00 美元。七位分析师对该股票给予持有评级，十七位分析师给予买入评级，一位分析师给予强力买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价格为 93.45 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on BioMarin Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>查看我们对药明康德的最新分析</strong></p>
</div><h2>BioMarin Pharmaceutical Price Performance</h2>
<div class="lb-trans"><h2>药明康德的价格表现</h2>
</div><ul>
<li>3 Oversold Stocks with Big RSI Rebound Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只超卖股票具有大幅反弹潜力</li>
</ul>
</div><p>NASDAQ:BMRN traded up $0.32 during trading hours on Monday, hitting $62.35. 214,200 shares of the stock traded hands, compared to its average volume of 1,857,035. The company has a market cap of $11.90 billion, a price-to-earnings ratio of 28.39, a price-to-earnings-growth ratio of 0.61 and a beta of 0.27. BioMarin Pharmaceutical has a 1 year low of $52.93 and a 1 year high of $94.85. The stock has a 50 day moving average price of $65.84 and a 200 day moving average price of $65.71. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11.</p>
<div class="lb-trans"><p>NASDAQ:BMRN 在周一的交易中上涨 0.32 美元，达到 62.35 美元。该股票交易了 214,200 股，较其平均交易量 1,857,035 股有所减少。该公司的市值为 119 亿美元，市盈率为 28.39，市盈增长比率为 0.61，贝塔值为 0.27。药明康德的 1 年最低价为 52.93 美元，1 年最高价为 94.85 美元。该股票的 50 日移动平均价格为 65.84 美元，200 日移动平均价格为 65.71 美元。该公司的速动比率为 2.62，流动比率为 5.33，债务股本比率为 0.11。</p>
</div><p>BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The company had revenue of $747.31 million during the quarter, compared to the consensus estimate of $711.05 million. Sell-side analysts forecast that BioMarin Pharmaceutical will post 3.15 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>药明康德（NASDAQ:BMRN - 获取免费报告）最近在 2 月 19 日发布了其财报。这家生物技术公司报告本季度每股收益为 0.72 美元，超出市场共识预期的 0.54 美元，超出幅度为 0.18 美元。药明康德的净利润率为 14.96%，股本回报率为 9.91%。该公司本季度的收入为 7.4731 亿美元，超过市场共识预期的 7.1105 亿美元。卖方分析师预测药明康德在当前财政年度将发布 3.15 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>药明康德的内部买卖情况</h2>
</div><ul>
<li>Are Gene Therapy Stocks The Market's Next Big Winners?</li>
</ul>
<div class="lb-trans"><ul>
<li>基因治疗股票会成为市场下一个大赢家吗？</li>
</ul>
</div><p>In other news, CAO Erin Burkhart sold 1,295 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $71.52, for a total value of $92,618.40. Following the transaction, the chief accounting officer now directly owns 16,955 shares in the company, valued at approximately $1,212,621.60. This represents a 7.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.85% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席会计官 Erin Burkhart 在 3 月 19 日的交易中出售了 1,295 股该公司的股票。这些股票的平均售价为 71.52 美元，总价值为 92,618.40 美元。交易后，首席会计官现在直接持有该公司 16,955 股股票，价值约为 1,212,621.60 美元。这代表着他们持有的股票减少了 7.10%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站访问。目前，企业内部人士持有该股票的 0.85%。</p>
</div><h2>Hedge Funds Weigh In On BioMarin Pharmaceutical</h2>
<div class="lb-trans"><h2>对药明康德的对冲基金看法</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in BioMarin Pharmaceutical during the 4th quarter worth $234,645,000. Capital Research Global Investors increased its stake in shares of BioMarin Pharmaceutical by 23.8% during the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock valued at $853,944,000 after buying an additional 2,496,817 shares during the period. Soleus Capital Management L.P. bought a new stake in shares of BioMarin Pharmaceutical in the fourth quarter valued at about $65,822,000. Dodge &amp; Cox lifted its stake in BioMarin Pharmaceutical by 6.1% in the fourth quarter. Dodge &amp; Cox now owns 14,746,235 shares of the biotechnology company's stock worth $969,270,000 after acquiring an additional 847,917 shares during the period. Finally, AQR Capital Management LLC grew its holdings in BioMarin Pharmaceutical by 114.5% during the 4th quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company's stock worth $84,371,000 after acquiring an additional 685,099 shares in the last quarter. 98.71% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近增加或减少了对该股票的持仓。挪威银行在第四季度购买了药明康德的新头寸，价值 234,645,000 美元。资本研究全球投资者在第四季度将其在药明康德的持股增加了 23.8%。资本研究全球投资者目前持有药明康德的 12,991,772 股股票，价值 853,944,000 美元，在此期间又购买了 2,496,817 股。Soleus Capital Management L.P.在第四季度购买了药明康德的新股份，价值约为 65,822,000 美元。Dodge &amp; Cox 在第四季度将其在药明康德的持股增加了 6.1%。Dodge &amp; Cox 目前持有药明康德的 14,746,235 股股票，价值 969,270,000 美元，在此期间又收购了 847,917 股。最后，AQR 资本管理公司在第四季度将其在药明康德的持股增加了 114.5%。AQR 资本管理公司目前持有药明康德的 1,283,599 股股票，价值 84,371,000 美元，在上个季度又收购了 685,099 股。目前，98.71% 的股票由机构投资者持有。</p>
</div><h2>BioMarin Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>药明康德公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.</p>
<div class="lb-trans"><p>药明康德公司开发和商业化针对严重和危及生命的罕见疾病及医疗状况的治疗方案。其商业产品包括 Vimizim，一种用于治疗粘多糖贮积症（MPS）IV 型 A 的酶替代疗法；Naglazyme，一种用于 MPS VI 患者的重组 N-乙酰半乳糖胺 4-硫酸酶；以及 Kuvan，一种用于治疗苯丙酮尿症（PKU）患者的专有合成口服 6R-BH4。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than BioMarin Pharmaceutical</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>3 Stocks to Watch as Bitcoin Nears $100k Again</li>
<li>The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number</li>
<li>Amazon: Why The Great Comeback Rally Could Be About to Begin</li>
<li>3 Small Caps With Big Return Potential</li>
<li>3 Reasons Tesla Should Be a $300 Stock by June</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过药明康德</li>
<li>如何使用 MarketBeat 股票筛选器</li>
<li>比特币再次接近 10 万美元时的 3 只关注股票</li>
<li>万亿美元市值的意义超越数字</li>
<li>亚马逊：伟大反弹的原因可能即将开始</li>
<li>3 只小盘股具有大幅回报潜力</li>
<li>3 个理由说明特斯拉应该在 6 月成为 300 美元的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Qk1STg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BMRN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in BioMarin Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在拜玛林制药吗？</h2>
</div><p>Before you consider BioMarin Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑拜玛林制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而拜玛林制药并不在名单上。</p>
</div><p>While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然拜玛林制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

高盛集团将拜玛林制药（NASDAQ:BMRN）的目标股价下调至 104.00 美元